Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Zimmer Biomet (NYSE:ZBH) and the rest of the surgical equipment & consumables - diversified stocks fared in Q3.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Date: January 14, 2026 Introduction Since its high-profile separation from industrial conglomerate 3M Company (NYSE: MMM) in April 2024, Solventum Corporation (NYSE: SOLV) has undergone a profound transformation. Once a steady but overshadowed healthcare division, Solventum has emerged as a focused, multi-billion-dollar medtech powerhouse. As of early 2026, the company is in the spotlight for [...]
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Zimmer Biomet (ZBH) presents a value investing case, trading at a significant discount to the market and its industry while maintaining solid profitability and financial health.
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more traditional value sectors and defensive equities. This ongoing recalibration reflects evolving macroeconomic conditions, a reassessment of risk appetite, and a growing
Zimmer Biomet (ZBH) presents a compelling value investment case with strong valuation metrics, solid earnings capability, and a stable balance sheet in the healthcare sector.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
Zimmer Biomet beats Q3 earnings estimates with strong U.S. sales, driven by new products, while reaffirming 2025 guidance and narrowing growth outlook.
The financial markets are a constant ebb and flow, and recently, the tide has pulled several prominent companies down to their 52-week lows. Among them, real estate investment trust Douglas Emmett (NYSE: DEI) and medical device giant Zimmer Biomet Holdings, Inc. (NYSE: ZBH) stand out. Their recent stock performance reflects
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.7% year on year to $2.00 billion. Its non-GAAP profit of $1.90 per share was 2.1% above analysts’ consensus estimates.
